Sanofi is buying the maker of a hepatitis B vaccine for $2.2 billion. The deal adds a hepatitis B vaccine to its portfolio. In addition, it is also acquiring a shingles vaccine. The acquisition strengthens Sanofi's vaccine offering. The value of the transaction amounts to $2.2 billion. The deal specifically includes these two vaccines. This expands Sanofi's existing portfolio.